CJC-1295 with DAC vs CJC-1295 without DAC (Modified GRF 1-29)
"CJC-1295" is used loosely in the peptide space to refer to two related but pharmacologically distinct molecules. CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog covalently linked via a maleimidopropionic acid spacer to serum albumin, giving it a multi-day half-life. CJC-1295 without DAC — which is more accurately called Modified GRF 1-29 or Mod GRF 1-29 — is the same 29-amino-acid sequence without the albumin-binding linker, clearing in about 30 minutes. They are often marketed under the same "CJC-1295" name and sold on adjacent shelves, but they produce fundamentally different GH exposure patterns and are used differently in clinical and biohacking protocols.
CJC-1295
A growth hormone-releasing hormone analog that stimulates the pituitary gland to produce more growth hormone.
CJC-1295 (no DAC)
A modified growth hormone releasing hormone analog with a shorter half-life than DAC-conjugated CJC-1295, allowing more physiological GH pulsing.
| Category | CJC-1295 | CJC-1295 (no DAC) |
|---|---|---|
| Molecular Structure | Modified GRF 1-29 (29 amino acids with 4 substitutions for stability) covalently linked to a maleimidopropionic acid (MPA) spacer that binds serum albumin via cysteine-34 | Modified GRF 1-29 (29 amino acids with 4 substitutions: D-Ala²-Gln⁸-Ala¹⁵-Leu²⁷) — the same peptide as CJC-DAC without the albumin-binding linker |
| More Precise Name | CJC-1295 (ConjuChem's original designation; 'with DAC' clarifies vs. the unlinked form) | Modified GRF 1-29 / Mod GRF 1-29 / CJC-1295 (no DAC) — often confusingly marketed under the same 'CJC-1295' umbrella |
| Half-Life | ~6–8 days (sustained albumin-bound circulation) | ~30 minutes (cleared rapidly via enzymatic degradation and renal clearance) |
| GH Release Pattern | Sustained, relatively flat GHRH-receptor stimulation — 'GH bleed' pattern with elevated baseline and blunted pulses | Discrete GH pulses following each injection — preserves the physiologic pulsatile pattern that mirrors endogenous GHRH |
| IGF-1 Response | Larger sustained IGF-1 elevation due to continuous receptor stimulation — some clinicians view this as the primary reason to choose DAC, others as the primary concern | More modest IGF-1 rise following each pulse, typically closer to high-physiologic range than supraphysiologic |
| Dosing Frequency | 1–2× per week (typically 2mg per injection for 2×/week protocols, or a single weekly dose) | 1–3× per day (typically 100 mcg per injection, timed before bed and/or post-workout to align with natural GH pulses) |
| Typical Stacking Partner | Ipamorelin daily before bed (the CJC-DAC supplies sustained GHRH signal, Ipamorelin adds pulsatile ghrelin-receptor triggers) | Ipamorelin at the same injection site and timing (Mod GRF 1-29 + Ipamorelin stacked before bed is a classic pulsatile biohacking protocol) |
| Physiology Philosophy | Non-physiologic — GH secretion in healthy adults is strongly pulsatile, and sustained GHRH stimulation departs from that pattern. Advocates argue the IGF-1 elevation matters more than pulse architecture; skeptics argue receptor desensitization and loss-of-feedback are real concerns. | Physiologic — preserves the endogenous GH pulse rhythm, which is hypothesized to be important for downstream IGF-1 signaling, sleep-wake coupling of GH, and avoiding receptor desensitization. |
| Onset of Measurable Effect | 1–2 weeks to see IGF-1 rise on labs; body composition / recovery effects typically 6–12 weeks | IGF-1 response detectable within days of consistent dosing; body composition / recovery effects on the same 6–12 week timeline |
| Common Side Effects | Water retention and facial puffiness (more pronounced than no-DAC), numbness/tingling in extremities, lethargy, injection site reactions — generally proportional to the sustained exposure | Injection site flushing or tingling, transient mild water retention, occasional pre-bed warmth/sleepiness — generally better tolerated than DAC at typical doses |
| Convenience | High — a single weekly injection covers the full week | Lower — requires daily (sometimes multiple-times-daily) injections, usually timed to sleep or training |
| Clinical Monitoring | IGF-1 trending; higher ceiling and less predictable interpretation due to non-pulsatile exposure — one argument against DAC is that IGF-1 can drift into supraphysiologic range on typical protocols | IGF-1 trending with more straightforward physiologic interpretation; fasting glucose and HbA1c as with any GH-axis intervention |
| FDA Status | Not FDA-approved. Historically available through 503A compounding pharmacies; the FDA's 2023 review narrowed that access pathway. ConjuChem's original development program reached Phase II and was not completed. | Not FDA-approved. Historically available through 503A compounding pharmacies, similarly constrained by the 2023 FDA review. Mod GRF 1-29 is often the more accessible of the two in current compounded-peptide channels. |
| WADA Status | Prohibited at all times under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). Detection assays have been validated and athletes have been sanctioned for CJC-1295 use. | Prohibited at all times under S2. Shorter half-life does not materially change detection-window risk at typical use frequencies. |
| Cost (Compounded, Monthly) | ~$100–250 depending on dose and pharmacy | ~$80–200; often the cheaper per-month option when used without CJC-DAC |
| Best Candidate Profile | Users prioritizing convenience of less-frequent dosing and willing to accept a non-pulsatile exposure pattern; tolerating more water-retention side effects in exchange for sustained IGF-1 elevation | Users prioritizing physiologic GH pulse architecture, lower side-effect burden, and tighter control over timing — commonly paired with Ipamorelin for the best-tolerated daily injectable GH-secretagogue protocol |
Summary
The core question dividing CJC-1295 with DAC from CJC-1295 without DAC (Mod GRF 1-29) is whether you want sustained GHRH receptor stimulation or preserved pulsatile GH release — the peptides are otherwise nearly identical in sequence. DAC (Drug Affinity Complex) is a covalent linker that binds serum albumin, dragging the peptide's half-life from about 30 minutes out to several days. That single modification is the entire difference, and it cascades into everything downstream: dosing frequency, GH pattern, IGF-1 response, side effect profile, and philosophical stance on physiologic vs non-physiologic growth-axis stimulation. CJC-1295 with DAC is the convenience option. A once- or twice-weekly injection produces sustained GHRH receptor activation that elevates IGF-1 to a higher and flatter level than a pulsatile protocol can achieve. For users who prioritize simplicity and want measurable IGF-1 rise on minimal injection burden, DAC is the logical choice. The trade-offs are real: water retention and facial puffiness are more prominent, the non-pulsatile exposure pattern departs from endogenous GH physiology in ways whose long-term consequences are not well characterized, and some clinicians argue that sustained receptor stimulation risks downregulation and loss-of-feedback effects that pulsatile dosing avoids. CJC-1295 without DAC — more accurately called Modified GRF 1-29 — is the pulsatile option. Each 100 mcg injection produces a discrete GH pulse similar in shape to what endogenous GHRH would generate, and IGF-1 rises more modestly. Daily dosing (often paired with Ipamorelin at the same injection, which adds a ghrelin-receptor pulse to the GHRH pulse) is the mainstream biohacking protocol for users who want GH-axis stimulation without departing from physiologic patterns. Side effects are generally milder, and the dose-response is more controllable. The cost is injection frequency — you are committing to daily (sometimes multiple-times-daily) subcutaneous injections rather than a once-weekly convenience schedule. The naming confusion matters. Many compounded-peptide vendors sell both as "CJC-1295" without clearly distinguishing, which has led to users unknowingly switching pharmacology when they change vendors. If you are buying "CJC-1295," specifically confirm whether it is the DAC-conjugated or the no-DAC form — and if the vendor cannot tell you, that is itself a signal about their quality control. Neither form is FDA-approved for any indication. ConjuChem's original development program for DAC-conjugated CJC-1295 reached Phase II and was abandoned. Both peptides sit in the compounded-peptide gray zone that the FDA's 2023 review has narrowed, and both are prohibited under WADA S2 at all times. Use should be under clinician supervision with IGF-1, fasting glucose, and body-composition monitoring, and neither should be treated as a substitute for foundational sleep, resistance training, and nutrition inputs that drive endogenous GH rhythm.
These peptides are often used together. See our stack profiles for combination details.